

## Prof. Taner KORKMAZ

### Personal Information

**Email:** taner.korkmaz@acibadem.edu.tr

**Web:** <https://avesis.acibadem.edu.tr/taner.korkmaz>

### International Researcher IDs

ORCID: 0000-0003-4292-0545

Yoksis Researcher ID: 172312

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study**  
Hizal M., BİLGİN B., Paksoy N., Kilickap S., Atci M. M., Kahraman S., Keskinilic M., Bilgetekin I., Ayhan M., Tural D., et al.  
FUTURE ONCOLOGY, no.23, pp.2573-2582, 2022 (SCI-Expanded)
- II. **Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer**  
Dinc N. S., Aydin K., Odabas H., Ercelep O., Tufan G., ŞEKER M., Yasar N., Aydin D., Yuksel S., Mert A., et al.  
ONCOLOGY RESEARCH AND TREATMENT, vol.39, no.3, pp.130-134, 2016 (SCI-Expanded)
- III. **Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis**  
Genestreti G., Tiseo M., Kenmotsu H., Kazushige W., Di Battista M., Cavallo G., Carloni F., Bongiovanni A., Burgio M. A., Casanova C., et al.  
CLINICAL LUNG CANCER, vol.16, no.6, 2015 (SCI-Expanded)
- IV. **Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience**  
Cabuk D., BAŞARAN G., Teomete M., Dane F., Korkmaz T., Seber S., Telli F., Yumuk P. F., Turhal S.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.1, pp.117-122, 2014 (SCI-Expanded)
- V. **Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis**  
Korkmaz T., Seber S., KEFELİ U., Sari E., Canhoroz M., Oven B., Yildirim E., Yasar N., Aydin D., Balvan O., et al.  
CLINICAL & TRANSLATIONAL ONCOLOGY, vol.15, no.7, pp.535-540, 2013 (SCI-Expanded)
- VI. **Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer**  
Korkmaz T., Seber S., Okutur K., BAŞARAN G., Yumuk F., Dane F., ÖNEŞ T., Polat O., Madenci O. C., Demir G., et al.  
BIOMARKERS, vol.18, no.1, pp.88-94, 2013 (SCI-Expanded)
- VII. **Clinical outcome of breast cancer patients with N3a ( $\geq 10$  positive lymph nodes) disease: has it changed over years?**  
BAŞARAN G., Devrim C., Çağlar H. B., GÜLLÜOĞLU M. B., KAYA H., Seber S., Korkmaz T., Telli F., Kocak M., Dane F., et al.  
MEDICAL ONCOLOGY, vol.28, no.3, pp.726-732, 2011 (SCI-Expanded)

### Articles Published in Other Journals

- I. **Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study**  
Turhal N. S., SAVAŞ B., COŞKUN Ö., Bas E., Karabulut B., Nart D., KORKMAZ T., Yavuzer D., Demir G., Dogusoy G., et al.  
MOLECULAR AND CLINICAL ONCOLOGY, no.6, pp.1275-1279, 2015 (ESCI)

## **Metrics**

Publication: 43  
Citation (WoS): 251  
Citation (Scopus): 217  
H-Index (WoS): 10  
H-Index (Scopus): 9

## **Congress and Symposium Activities**

Hedef KANSER , Moderator, Girne, Cyprus (Kktc), 2022  
8. Türk Tıbbi Onkoloji Kongresi , Invited Speaker, Antalya, Turkey, 2021